Q32 Bio Welcomes Dr. Adrien Sipos as Interim Chief Medical Officer Q32 Bio Inc. announces the appointment of Dr. Adrien Sipos as the Interim Chief Medical Officer, succeeding Dr. Jason Campagna, to drive the development of innovative therapies for alopecia areata.

Q32 Bio Welcomes Dr. Adrien Sipos as Interim Chief Medical Officer #United_States #Waltham #Q32_Bio #Bempikibart #Adrien_Sipos